KRAS and cancer: It was found that BRAF V600E, RET/PTC1 and TERT mutations were associated with aggressive characteristics, whereas BRAF K601E, HRAS, NRAS, KRAS, PAX8-PPARy mutations and tumors with no mutations are significantly less likely to be associated with high risk cancers.